Accessibility Menu
Myomo logo

Myomo(NYSEMKT) MYO

Market Cap$57.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-99%
5 Year-85%
1 Year+39%
1 Month+33%
$1.52
+4.11%
+0.06Today
Myomo last closing stock price
MetricPriceDate
Last closeUSD 1.462026-08-13
Myomo stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.45%USD 1.312026-08-06
1 month+32.73%USD 1.102026-07-14
3 month+60.42%USD 0.912026-05-15
Year to date+60.44%USD 0.912025-12-31
1 year+39.05%USD 1.052025-08-13
3 year+108.63%USD 0.702023-08-14
5 year-84.93%USD 9.692021-08-13
Since inception-99.34%USD 222.002017-06-12

Myomo Financials at a Glance

Market Cap

$57.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$43.26M

Net Income (TTM)

-$14.51M

EPS (TTM)

-$0.34

P/E Ratio

-4.26

Dividend

$0.00

Beta (Volatility)

1.30 (Average)

Price

$1.52

Volume

327,637.188

Open

$1.44

Previous Close

$1.46

Daily Range

$1.42 - $1.56

52-Week Range

$0.61 - $1.59

Estimated Earnings Date

Nov 9, 2026

MYO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Myomo

Myomo makes wearable robotic braces that help people move weak arms. Its main product, MyoPro, supports daily activities for those with arm paralysis. The company’s devices are used by patients with conditions like stroke or nerve injury.

Products and Services

  • MyoPro Motion G: Powered arm brace for adults and teens; 96% of 2025 product revenue.
  • MyoPro Motion W: Non-powered wrist support for upper limb weakness; smaller revenue share.
  • MyoPro 2x: Enhanced brace with easier use and 3D-printed parts; launched April 2025.
  • MyoPal: Pediatric device for children with arm paralysis; in development.
  • MyoGames & MyoConnect: Training games and referral programs for patients and therapists.

Growth and Expansion

  • Launched MyoPro 2x in April 2025, adding new features and 3D printing.
  • Expanded manufacturing by moving to a larger Burlington, MA headquarters in 2025.
  • Entered new markets through partnerships with O&P providers in the UK, Denmark, Germany, Italy, and Australia (2025).
  • Secured regulatory approvals in Europe (CE mark) and Canada (2025).
  • Formed a joint venture in China, though operations are limited due to partner bankruptcy.

What Makes Myomo Stand Out

Myomo’s devices use muscle signals to help people regain arm movement. The company holds 35 patents and custom-builds each device for individual needs. Its products are covered by Medicare and have regulatory clearance in the US, EU, and Canada.

Five Things You Need to Know

  • Revenue was $40.93 million in 2025, up 26% from 2024.
  • Direct billing made up 74% of 2025 revenue; international sales were 17%.
  • Gross margin fell to 65.7% in 2025, down from 71.2% in 2024.
  • Operating loss was $14.40 million in 2025, more than double 2024’s loss.

Bottom Line

Myomo has grown by expanding its product line and global reach. The company focuses on innovation and adapting to changing healthcare needs.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

195

CEO

Paul R. Gudonis, MBA

Website

www.myomo.com

Headquarters

Burlington, MA 01803, US

MYO Financials

Key Financial Metrics (TTM)

Gross Margin

68.35%

Operating Margin

-27.05%

Net Income Margin

-33.53%

Return on Equity

-142.02%

Return on Capital

-46.78%

Return on Assets

-41.05%

Earnings Yield

-23.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$57.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

39.61M

Volume

327.64K

Avg. Volume

846.59K

Financials (TTM)

Gross Profit

$29.57M

Operating Income

-$11.70M

EBITDA

-$11.39M

Operating Cash Flow

-$7.11M

Capital Expenditure

-$1.72M

Free Cash Flow

-$8.83M

Cash & ST Invst.

$13.45M

Total Debt

$20.08M

Myomo Performance Analysis

Myomo annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 15,555,22912.3%
20232023-12-31USD 19,241,15823.7%
20242024-12-31USD 32,551,19969.2%
20252025-12-31USD 40,928,04225.7%
Myomo sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-304.5%
Q42025-12-3112.5%
Q12026-03-31-10.9%
Q22026-06-3015.7%
Myomo annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.52-19.5%
20232023-12-31USD -0.28-81.8%
20242024-12-31USD -0.16-40.7%
20252025-12-31USD -0.37127.2%
Myomo sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3018.2%
Q42025-12-31-0.4%
Q12026-03-3122.6%
Q22026-06-30-28.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$11.70M

+21.3%

Gross Profit

$8.44M

+39.5%

Gross Margin

72.13%

N/A

Market Cap

$57.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$296.55K

N/A

Employees

195

N/A

Net Income

-$4.02M

+13.2%

EBITDA

-$3.45M

+14.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$13.45M

-13.1%

Total Debt

$20.08M

+61.5%

Accounts Receivable

$4.95M

-29.9%

Inventory

$3.17M

-23.2%

Long Term Debt

$18.90M

+103.2%

Short Term Debt

$1.18M

-62.3%

Return on Assets

-41.05%

N/A

Return on Invested Capital

-47.32%

N/A

Free Cash Flow

-$1.62M

+84.0%

Operating Cash Flow

-$1.94M

+78.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
POCIPrecision Optics Corporation, Inc.
$4.41+4.88%
HYPDHyperion DeFi, Inc.
$2.78-1.77%
MIRAMIRA Pharmaceuticals, Inc.
$0.80+7.28%
ECORelectroCore, Inc.
$10.00+0.55%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.37+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.60-0.00%
INTCIntel
$103.04-0.01%
ONDSOndas
$9.47+0.06%

Questions About MYO

What is the current price of Myomo?

Myomo is trading at $1.52 per share.

What is the 52-week range for Myomo?

Over the past 52 weeks, Myomo has traded between $0.61 and $1.59.

How much debt does Myomo have?

As of the most recent reporting period, Myomo reported total debt of $20.08M.

How much cash does Myomo have on hand?

Myomo reported $11.22M in cash and cash equivalents in its most recent financial results.

What is Myomo’s dividend yield?

Myomo does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services